Inhibrx Biosciences, Inc. (INBX)

Inhibrx Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	124.22	152.6	277.92	273.87	131.3
Cash & Short-Term Investments	124.22	152.6	277.92	273.87	131.3
Cash Growth	-18.60%	-45.09%	1.48%	108.58%	2.05%
Accounts Receivable	-	0.2	0.78	0.24	0.37
Other Receivables	0.18	0.22	-	0.01	0.51
Total Trade Receivables	0.18	0.42	0.78	0.26	0.88
Other Current Assets	8.44	7.38	16.66	6.37	6.93
Total Current Assets	132.83	160.4	295.36	280.49	139.11
Net Property, Plant & Equipment	9.27	13.54	9.37	7.22	9.49
Other Long-Term Assets	4.38	6.83	3.16	3.16	1.85
Total Assets	146.48	180.77	307.89	290.88	150.45
Accounts Payable	5.94	9.25	10.95	8.33	-
Accrued Expenses	25.53	29.89	43.3	17.22	9.62
Current Portion of Leases	2.33	1.6	2.06	1.86	1.67
Unearned Revenue	-	-	-	0.17	2.03
Total Current Liabilities	33.8	40.73	56.31	27.58	22.45
Long-Term Debt	100.56	-	206.97	202.07	70.47
Long-Term Leases	4.13	6.45	1.11	3.17	5.03
Other Long-Term Liabilities	-	-	-	-	0.11
Total Long-Term Liabilities	104.69	6.45	208.08	205.24	75.61
Total Liabilities	138.49	47.18	264.39	232.82	98.07
Common Stock	0	0	0.01	0	0
Additional Paid-in Capital	254.18	239.72	657.23	430.43	279.53
Retained Earnings	-246.19	-106.13	-613.73	-372.37	-227.15
Shareholders' Equity	7.99	133.58	43.5	58.06	52.38
Total Liabilities & Equity	146.48	180.77	307.89	290.88	150.45
Total Debt	107.01	8.05	210.14	207.1	77.18
Net Cash (Debt)	17.21	144.55	67.78	66.76	54.12
Net Cash Growth	-88.09%	113.25%	1.53%	23.35%	-40.66%
Net Cash Per Share	1.11	9.65	5.75	1.67	1.42
Book Value	7.99	133.58	43.5	58.06	52.38
Book Value Per Share	0.52	8.92	3.69	1.45	1.38
Tangible Book Value	7.99	133.58	43.5	58.06	52.38
Tangible Book Value Per Share	0.52	8.92	3.69	1.45	1.38

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q